Strata Critical Medical financials
$5.10−2.49%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 |
|---|---|---|---|---|
| Revenue | $72.5M | $67.4M | $66.8M | $49.3M |
| Gross profit | $15.2M | $14.1M | $11.7M | $11.6M |
| Gross margin | 21.0% | 21.0% | 17.5% | 23.6% |
| Operating income | -$5.4M | -$3.0M | -$6.4M | -$5.6M |
| Net income | -$10.5M | $2.2M | -$8.8M | $57.4M |
| Net margin | −14.5% | 3.2% | −13.2% | 116.5% |
| Diluted EPS | $-0.12 | $0.03 | $-0.10 | $0.70 |
| EBITDA | $3.1M | $86.0K | -$3.4M | -$3.9M |
| Operating cash flow | $5.7M | $3.9M | -$8.3M | -$37.3M |
| Free cash flow | $3.2M | -$1.3M | -$10.2M | -$40.1M |
| Diluted shares | 86.2M | 85.3M | 84.7M | 82.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 |
|---|---|---|---|---|
| Cash & equivalents | $16.3M | $58.7M | $31.0M | $22.8M |
| Short-term investments | $6.4M | $66.0K | $30.3M | $53.2M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $332.7M | $327.6M | $325.5M | $335.1M |
| Total liabilities | $53.4M | $41.9M | $46.4M | $52.1M |
| Shareholders' equity | $279.3M | $285.7M | $279.1M | $283.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology